Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: A 15-year follow-up of the Chinese Multi-provincial Cohort Study

Diabetes Research and Clinical Practice

Volumn 96, Issue 2, 2012, Pages 217-224

  Liu, Jing ^a   Wang, Wei ^a   Wang, Miao ^a   Sun, Jiayi ^a   Liu, Jun ^a   Li, Yan ^a   Qi, Yue ^a   Wu, Zhaosu ^a   Zhao, Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cardiovascular disease; Diabetes; Dyslipidemia; Prospective cohort study

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGING; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION PREVENTION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; OBESITY; PROSPECTIVE STUDY; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STROKE; TRIGLYCERIDES;

EID: 84862805395     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.12.018     Document Type: Article

References (36)

1. Gordon T., Kannel W.B., Castelli W.P., Dawber T.R. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Int Med 1981, 141(9):1128-1131.
2. Imamura T., Doi Y., Arima H., Yonemoto K., Hata J., Kubo M., et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population. The Hisayama Study. Stroke 2008, 40(2):382-388.
3. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 2001, 285(19):2486-2497.
4. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347(20):1557-1565.
5. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352(14):1425-1435.
6. Criqui M.H., Heiss G., Cohn R., Cowan L.D., Suchindran C.M., Bangdiwala S., et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993, 328(17):1220-1225.
7. Cambien F., Jacqueson A., Richard J.L., Warnet J.M., Ducimetiere P., Claude J.R. Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? The Paris Prospective Study. Am J Epidemiol 1986, 124(4):624-632.
8. Sacks F.M., Tonkin A.M., Craven T., Pfeffer M.A., Shepherd J., Keech A., et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002, 105(12):1424-1428.
9. Carroll M.D., Lacher D.A., Sorlie P.D., Cleeman J.I., Gordon D.J., Wolz M., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005, 294(14):1773-1781.
10. Ferrieres J., Bongard V., Dallongeville J., Arveiler D., Cottel D., Haas B., et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. Arch Cardiovasc Dis 2009, 102(4):293-301.
11. Ford E.S., Li C., Zhao G., Pearson W.S., Mokdad A.H. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Int Med 2009, 169(6):572-578.
12. Zhao W.H., Zhang J., Zhai Y., You Y., Man Q.Q., Wang C.R., et al. Blood lipid profile and prevalence of dyslipidemia in Chinese adults. Biomed Environ Sci 2007, 20(4):329-335.
13. Liu J., Hong Y., D'Agostino R.B., Wu Z., Wang W., Sun J., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004, 291(21):2591-2599.
14. Zhao D., Grundy S.M., Wang W., Liu J., Zeng Z., Wang W., et al. Ten-year cardiovascular disease risk of metabolic syndrome without central obesity in middle-aged chinese. Am J Cardiol 2007, 100(5):835-839.
15. Liu J., Grundy S.M., Wang W., Smith S.C., Vega G.L., Wu Z., et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007, 153(4):552-558.
16. Wu Z., Yao C., Zhao D., Wu G., Wang W., Liu J., et al. Cardiovascular disease risk factor levels and their relations to CVD rates in China - results of Sino-MONICA project. Eur J Cardiovasc Prev Rehabil 2004, 11(4):275-283.
17. WHO MONICA Project. MONICA manual. Available from: [accessed 17.10.2009]. http://www.ktl.fi/publications/monica/manual/index.htm.
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
19. Wu Z., Yao C., Zhao D., Wu G., Wang W., Liu J., et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China. Part i: morbidity and mortality monitoring. Circulation 2001, 103(3):462-468.
20. MONICA Manual, Part III: population survey, Section 2: standardization of lipid measurements. Available from: [accessed 8.11.2011]. http://www.ktl.fi/publications/monica/manual/part3/iii-2.htm.
21. Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 2003, 26(Suppl 1):S5-S20.
22. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
23. Winter Y., Rohrmann S., Linseisen J., Lanczik O., Ringleb P.A., Hebebrand J., et al. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke 2008, 39(12):3145-3151.
24. Wildman R.P., Gu D., Reynolds K., Duan X., Wu X., He J. Are waist circumference and body mass index independently associated with cardiovascular disease risk in Chinese adults?. Am J Clin Nutr 2005, 82(6):1195-1202.
25. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart. Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
26. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1563-1574.
27. Arsenault B.J., Rana J.S., Stroes E.S., Despres J.P., Shah P.K., Kastelein J.J., et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009, 55(1):35-41.
28. Simons L.A., Simons J., Friedlander Y., McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001, 159(1):201-208.
29. Goldstein L.B., Bushnell C.D., Adams R.J., Appel L.J., Braun L.T., Chaturvedi S., et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42(2):517-584.
30. Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M.H., Ginsberg H.N., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123(20):2292-2333.
31. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32(14):1769-1818.
32. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009, 16(2):121-137.
33. Nayak B.S., Butcher D.M., Bujhawan S., Chang D., Chang S., Cabral-Samaroo D., et al. Association of low serum creatinine, abnormal lipid profile, gender, age and ethnicity with type 2 diabetes mellitus in Trinidad and Tobago. Diabetes Res Clin Pract 2011, 91(3):342-347.
34. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79(1):8-15.
35. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357(13):1301-1310.
36. Iso H., Sato S., Kitamura A., Imano H., Kiyama M., Yamagishi K., et al. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 2007, 38(6):1744-1751.